Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Religare Enterprises...

    Religare Enterprises to classify promoters as public shareholders

    Written by Ruby Khatun Khatun Published On 2018-08-13T10:45:14+05:30  |  Updated On 13 Aug 2018 10:45 AM IST
    Religare Enterprises to classify promoters as public shareholders

    New Delhi: Financial services conglomerate Religare Enterprise said the promoter and promoter groups of the company will be reclassified into a public shareholding category.


    "The Board of Directors has approved the proposal for re-classification of existing promoters and promoter group into the public shareholder category as requested by them, subject to the approval of shareholders of the company," Religare Enterprises said in a statement.


    Brothers Malvinder Mohan Singh and Shivinder Mohan Singh are the promoters of the company. While RHC Finance and RHC Holding are the promoter groups.



    The brothers and promotor groups have brought down their shareholding in the company substantially over a period of time on a number of factors as also Malvinder and Shivinder quit from the boards of Fortis and Religare Enterprises in February this year.

    As on June 30, 2018, Malvinder and Shivinder held 0.56 percent and 0.51 percent respectively in the company. While RHC Finance and RHC Holding had 0.99 percent and 0.95 percent respectively.


    The combined shareholding of the promoters and promoter groups now stands at 3.01 percent, substantially down from 50.93 percent as on June 30, 2016, and even before that time. Other family members of the company had also a significant stake in REL which now stands as nil.


    The billionaire Singh brothers faced an international arbitration with Japan's Daiichi Sankyo to make a payment of Rs 3,500 crore as the latter alleged that the former promoters of Ranbaxy Laboratories Ltd had concealed information about proceedings against them by the American food and drug department.


    Singh brothers had sold their shares in Ranbaxy to Daiichi in 2008 for Rs 9,576.1 crore. Sun Pharmaceuticals Ltd later acquired the company from Daiichi.


    The Delhi High Court in January this year upheld the international arbitral award in favour of Japanese pharma major.


    Religare also announced today that it has appointed Milind Patel as the Group Chief Executive Officer of the company, replacing the interim CEO Ashok Mehta.


    Mehta will stay on as non-executive non-independent director, subject to RBI approval, it said.


    Patel comes with over 26 years of financial experience and has worked in select multinational and domestic financial institutions on diverse mandates.


    A graduate in Commerce from Sydenham College, Mumbai and Cost and Works Accountancy from the ICWAI, Patel also holds an MBA degree from Jamnalal Bajaj Institute of Management Studies, Mumbai.


    Religare Enterprises has a host of subsidiaries engaged in the business of SME loans, housing finance, health insurance and retail broking among others.

    Ashok Mehtachief executive officerclassifyDaiichi SankyoDelhi high courtinternational arbitrationMalvinder Mohan SinghMilind PatelPromoterspublic shareholdersRanbaxy laboratoriesReligare EnterprisesRHC FinanceRHC HoldingShivinder Mohan SinghSingh brothers
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok